Psilocybin Therapy in Canada

Psilocybin therapy in Canada is legal medicine when accessed through the right regulatory pathway — and that pathway has one door: Health Canada's Special Access Program (SAP). As of the January 5, 2022 SAP amendment, physicians and nurse practitioners can apply on behalf of individual patients with serious or life-threatening conditions where conventional treatments have failed, are unsuitable, or are unavailable. There is no commercial pathway, no clinic where you can simply book a session, and no provincial drug formulary listing. Psilocybin remains a Schedule III substance under the Controlled Drugs and Substances Act with no Health Canada approved indication. The peer-reviewed evidence base — Griffiths 2016 and Ross 2016 in cancer-related anxiety/depression, Carhart-Harris 2016 and Davis 2021 and Goodwin 2022 in treatment-resistant depression, Bogenschutz 2022 in alcohol use disorder, Agrawal 2024 in cancer-related MDD with group therapy, Anderson 2020 in demoralization — is meaningful but emerging, and almost all of it sits outside Canada. Quebec became the first Canadian province to publicly fund psilocybin-assisted therapy in December 2022 (Farzin / Stephan billed RAMQ). The 2025 Canadian access landscape has tightened: PsyCan reported a sharp decline in SAP approvals through 2025. This hub article walks through what psilocybin therapy actually is, who it's evidence-supported for, how the SAP pathway works in 2026 Canada, what it costs, and how ATMA CENA fits in for patients pursuing this pathway.

Key takeaways

• Psilocybin is Schedule III under the CDSA; no Health Canada approved indication. Clinical access is via the Special Access Program (SAP) only since the January 5, 2022 amendment.
• SAP is physician/NP-initiated — patients cannot apply directly. Physicians document failed conventional treatments and submit a case-specific request to Health Canada.
• Approval rates are declining: ~78% historical approval rate per industry reporting; PsyCan reported a sharp decline through 2025 with cumulative approvals around 301 since the program opened.
• Quebec is the only province with established public funding (Farzin / Stephan billed RAMQ December 2022 for SAP-approved psilocybin therapy).
• Veterans Affairs Canada does not currently cover psilocybin (in contrast to ketamine, which VAC does cover for service-related TRD or chronic pain).
• ATMA CENA supports preparation and integration for SAP-pathway psilocybin patients via the coordinated care model and offers psychedelic-assisted therapy training. The medical SAP application is initiated by the patient's prescribing physician or nurse practitioner.
• Strongest evidence: end-of-life distress (Griffiths 2016, Ross 2016, Agrawal 2024); treatment-resistant depression (Carhart-Harris 2016, Davis 2021, Goodwin 2022); alcohol use disorder (Bogenschutz 2022).

What is psilocybin-assisted therapy?

Psilocybin-assisted therapy is a structured clinical model that pairs a single high-dose psilocybin session — typically 25 mg of synthetic pharmaceutical psilocybin — with preparation sessions before and integration sessions after. The dosing session is 6 to 8 hours in a clinical setting with two trained therapists present (in most published trial protocols), eye shades, curated music, and continuous monitoring. Effects begin 20 to 50 minutes after oral dosing, peak at 1.5 to 3 hours, and resolve over 4 to 6 hours total. The therapeutic mechanism is hypothesized to involve 5-HT2A serotonin receptor agonism, default mode network modulation, neuroplasticity, and the quality of the acute mystical-type experience as a mediator of long-term outcomes.

For the modality deep dive, see What Is Psilocybin Therapy?.

How psilocybin therapy differs from ketamine therapy

For the cross-treatment comparison, see Ketamine vs Psilocybin Therapy.

The Canadian regulatory framework — three layers

Federal — CDSA Schedule III

Psilocybin is controlled under Schedule III of the Controlled Drugs and Substances Act (CDSA). Schedule III status means controlled distribution and prescription-required where authorized — psilocybin is not approved by Health Canada for any therapeutic indication, so the standard prescribing path is closed. Recreational possession is illegal under the CDSA and carries criminal penalties.

The Canadian government framework is described at Canada.ca — Psilocybin and psilocin.

Health Canada — SAP, the only legal access pathway

The Special Access Program (SAP) is Health Canada's framework for physicians and nurse practitioners to request access to drugs that are not approved in Canada for individual patients with serious or life-threatening conditions. Two key dates anchor the modern Canadian psilocybin pathway:

• August 4, 2020: Health Canada granted Section 56(1) exemptions to four terminally ill Canadians for psilocybin-assisted therapy (TheraPsil-led advocacy). This was the first legal therapeutic psilocybin access in Canada in decades.
• January 5, 2022: Health Canada amended the SAP regulations to allow practitioner-initiated requests for psilocybin (and MDMA) for serious or life-threatening conditions where conventional treatments have failed, are unsuitable, or are unavailable. See the Health Canada SAP psychedelic-assisted psychotherapy notice.

The SAP request process, in short: a physician or nurse practitioner identifies an individual patient with documented failed conventional treatment, completes the SAP request form, submits it to Health Canada, and waits for case-specific authorization. The patient cannot apply directly. Once authorized, the practitioner sources the drug from a Health Canada-licensed Canadian producer (Filament Health, Optimi Health, Psyence Group are among the licensed suppliers) and administers it in a supervised clinical setting.

For the SAP deep dive, see How to Access Psilocybin Therapy in Canada.

Provincial — variable

Provincial medical regulators have not issued specific psilocybin policies in most jurisdictions. CPSA Alberta has issued psychedelic-assisted therapy guidance applicable to ATMA CENA's corporate clinic operations. CPSO Ontario has not issued a specific psilocybin policy; off-label psychotherapy is governed by CRPO oversight. CPSBC British Columbia and CMQ Quebec have similarly not issued specific psilocybin policies. Quebec's notable distinction is on the public-funding side — RAMQ has a precedent for billing psilocybin-assisted therapy, established by Drs. Houman Farzin and Jean-François Stephan in December 2022.

For a closer look at the legal layers, see Is Psilocybin Therapy Legal in Canada? (Wave 4 article).

What conditions is psilocybin SAP-approved for?

Health Canada SAP authorizations are case-specific. The most commonly approved indications are conditions with the strongest peer-reviewed evidence:

End-of-life distress and cancer-related psychiatric distress

The first SAP approvals (and the August 2020 Section 56 exemptions before them) were for end-of-life distress in patients with terminal illness. The evidence base:

• Griffiths et al. 2016 — Johns Hopkins double-blind RCT (N=51) in patients with life-threatening cancer. Single high-dose psilocybin (22 or 30 mg/70 kg) produced sustained decreases in depression and anxiety at 6-month follow-up (J Psychopharmacology 2016, PMID 27909164).
• Ross et al. 2016 — NYU double-blind RCT (N=29) in cancer-related anxiety/depression. Single 0.3 mg/kg psilocybin produced rapid and sustained antidepressant and anxiolytic effects at 6.5 months (J Psychopharmacology 2016).
• Agin-Liebes et al. 2020 — long-term follow-up of the Ross cohort. 60–80% maintained clinically significant response at 4–5 years (J Psychopharmacology, PMID 31916890).
• Agrawal et al. 2024 — Sunstone Therapies group-therapy phase II in cancer patients with MDD (N=30). Single 25 mg psilocybin with group therapy produced robust depression reduction at week 8 (Cancer 2024, PMID 38105655).
• Anderson et al. 2020 — pilot of psilocybin-assisted group therapy for demoralization in long-term AIDS survivors (N=18). Safety established; clinically meaningful improvement in demoralization at 3 months (EClinicalMedicine 2020, PMID 33150319).

For the deep dive on this indication, see Psilocybin Therapy for End-of-Life Distress.

Treatment-resistant depression

The second-most-common SAP-approved indication is treatment-resistant depression with documented failure of conventional antidepressant trials.

• Carhart-Harris et al. 2016 — Imperial College open-label trial (N=12) in TRD. Significant antidepressant effects at 1 week sustained at 3 months (Lancet Psychiatry 2016).
• Davis et al. 2021 — Johns Hopkins randomized trial (N=24) in MDD. Two psilocybin sessions with supportive psychotherapy produced ~71% response rate at 4 weeks (JAMA Psychiatry 2021).
• Goodwin et al. 2022 — COMP001 — Compass Pathways Phase 2b RCT (N=233) in TRD. Single 25 mg COMP360 psilocybin produced significantly greater MADRS reduction than 1 mg comparator at 3 weeks (NEJM 2022).

Alcohol use disorder

• Bogenschutz et al. 2022 — randomized double-blind trial (N=95) in alcohol use disorder. Two psilocybin sessions plus 12 weeks of psychotherapy produced substantial reduction in heavy drinking days versus diphenhydramine + same psychotherapy (JAMA Psychiatry 2022).

This is the strongest published AUD-specific evidence for any psychedelic-assisted therapy. See Ketamine Therapy for Addiction for the cross-treatment comparison framing.

Other indications

Smaller signals exist for OCD, anorexia, demoralization, cluster headache, and PTSD. SAP approvals for these are less common; PTSD-specific SAP applications more commonly target MDMA than psilocybin.

How psilocybin works — mechanism in brief

Psilocybin is rapidly converted to psilocin in the body. Psilocin binds 5-HT2A serotonin receptors as a partial agonist, with downstream effects including:

• Default mode network (DMN) modulation. Carhart-Harris et al. 2012, PNAS used fMRI to demonstrate that psilocybin decreases functional connectivity within the DMN — the network implicated in self-referential thought and rumination. The magnitude of DMN deactivation correlated with the intensity of subjective effects.
• Neuroplasticity. Ly et al. 2018, Cell Reports demonstrated that psilocybin promotes structural neuroplasticity — dendritic spine growth in frontal cortex neurons within hours of a single dose.
• Mystical experience as mediator. Roseman, Nutt, Carhart-Harris 2018, Frontiers in Pharmacology demonstrated that the quality of the acute psilocybin experience — particularly oceanic boundlessness — predicts therapeutic efficacy in TRD. The Mystical Experience Questionnaire, validated by MacLean, Johnson, Griffiths 2011, is the standard psychometric instrument for measuring this.

The honest framing: the mechanism story is plausible and supported by multiple converging lines of evidence, but mechanism-to-clinic translation in psychiatry is rarely linear, and direct mechanistic answers to "why does this work for some patients and not others" remain open research questions.

What does psilocybin therapy cost in Canada?

Psilocybin-assisted therapy through the SAP pathway typically costs CAD $2,500 to $6,500 per full treatment program, including preparation sessions, the dosing day with two therapists, and integration sessions. Major cost components:

• Preparation sessions (2–3 sessions): $150–$300 per session, standard Canadian psychotherapy rates.
• Dosing session (one 6–8 hour session with two therapists, clinical setting, monitoring): the largest single cost component.
• Integration sessions (2–4 sessions): $150–$300 per session.
• Drug cost: notably, Filament Health provides synthetic psilocybin to SAP-approved Canadian patients at no charge. This significantly reduces patient out-of-pocket relative to international markets.

For comparison: Australia's TGA-authorized pathway costs roughly AUD $15,000–$30,000 per course; Oregon's licensed psilocybin services average USD $1,500–$3,500 per session.

For the cost deep dive, see Psilocybin-Assisted Therapy Cost in Canada.

Insurance reality

• Public coverage: Quebec RAMQ is the only province where psilocybin-assisted therapy has been billed publicly (Farzin / Stephan, December 2022). Other provincial drug plans do not list psilocybin.
• Veterans Affairs Canada: does NOT currently cover psilocybin-assisted therapy. This is a meaningful contrast to ketamine, which VAC does cover for service-related TRD or chronic pain. See Ketamine Therapy for PTSD.
• Alberta Blue Cross PAT (March 2024): covers ketamine-assisted therapy. Psilocybin coverage was framed as future potential once formally legalized for therapy in Canada.
• Private extended-health insurance: therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy when delivered by a covered professional. Drug cost is essentially never covered by private insurance.

The Canadian provider landscape — who does this work?

The Canadian psilocybin therapy ecosystem is small but established. Major players:

• TheraPsil (Vancouver Island; founded 2019 by Dr. Bruce Tobin and Spencer Hawkswell). Advocacy, clinician training, patient SAP-application support. Helped secure the August 2020 Section 56 exemptions. Continues to train Canadian clinicians and provide free patient consultations.
• Numinus / Stella Mental Health (publicly traded; merged 2024). Clinical training program; multi-site presence; SAP-pathway support.
• Roots to Thrive (Nanaimo BC; partnership with Vancouver Island University and Snuneymuxw Community Wellness Centre). Group-based KAT model with published clinical protocol; first Canadian healthcare practice to legally offer SAP-pathway psilocybin-assisted group therapy for end-of-life patients. See Group Ketamine Therapy for the published Roots to Thrive ketamine protocol.
• P.A.T.H Therapy Canada — multi-provincial preparation and integration support.
• Neurotherapy Montreal — Quebec psychedelic-assisted psychotherapy clinic with active PAT services.
• Quebec collective: Drs. Houman Farzin (Jewish General Hospital palliative psychiatry) and Jean-François Stephan — first to bill RAMQ for psilocybin-assisted therapy December 2022. Dr. Valorie Masuda (BC palliative) was among the first SAP-approved psilocybin prescribers in March 2022.
• Psychedelics Canada (PsyCan) — trade association advocating for regulatory engagement and public education.

Canadian licensed psilocybin producers include Filament Health, Optimi Health, and Psyence Group.

Where ATMA CENA fits

ATMA CENA's corporate clinics are in Edmonton and Calgary, with member clinics across multiple provinces. For psilocybin-pathway patients specifically:

• The medical SAP application is initiated by the patient's prescribing physician or nurse practitioner — not by ATMA CENA directly. ATMA CENA's clinical team can discuss the regulatory context and what SAP applications typically require.
• ATMA CENA supports preparation and integration for patients pursuing the SAP pathway. The ATMA CENA three-phase KAP model — preparation, dosing support coordination, integration — adapts to psilocybin where SAP approval is in place.
• The coordinated care model lets a patient's existing therapist remain the primary therapeutic relationship while ATMA CENA's medical infrastructure provides oversight specific to the dosing session.
• ATMA CENA's training program includes psychedelic-assisted therapy training for clinicians who may go on to support SAP-pathway work. See the psychedelic therapy training cluster for detail.

The ATMA CENA intake call is the practical entry point for patients evaluating whether SAP-pathway psilocybin therapy is right for them and how ATMA CENA's preparation/integration model fits their pathway.

Who is a candidate? (Honest framing)

Most published psilocybin trials use the following inclusion criteria, and Health Canada SAP applications typically reflect them:

• Adults 18 or older
• Documented diagnosis of a serious or life-threatening condition (cancer-related psychiatric distress, treatment-resistant depression, alcohol use disorder, demoralization in serious illness)
• Documented failure of conventional treatments at adequate dose and duration
• Medically stable; able to provide informed consent

Absolute contraindications (consistent across published trials and clinical SAP framings):

• Personal history of psychotic disorder (schizophrenia, schizoaffective disorder, bipolar I)
• First-degree family history of psychotic disorder (more conservative framing)
• Active mania or recent hypomania
• Uncontrolled cardiovascular disease, recent MI, severe structural heart disease
• Pregnancy
• Concurrent lithium (seizure case reports)
• Active substance use disorder requiring treatment

Relative contraindications: high-dose serotonergic antidepressants (theoretical serotonin syndrome risk; many trials taper or hold SSRIs/SNRIs); severe personality disorder with marked instability; complex trauma without adequate prep capacity.

For the eligibility detail, see the SAP-access deep dive in How to Access Psilocybin Therapy in Canada.

The 2025 access tightening — honest framing

The Canadian psilocybin SAP landscape changed materially through 2025. PsyCan reported a sharp decline in Health Canada SAP approvals across the year — by mid-2025 cumulative approvals had reached approximately 301 since the program's January 2022 launch, with monthly approval rates falling significantly compared to 2023–2024 highs. Approval timelines lengthened. Physician reluctance to apply (driven by limited training, comfort, and the eight-page SAP request form's documentation burden) compounded the bottleneck.

The honest takeaway: legal psilocybin access in Canada is real but narrowing. Patients pursuing this pathway in 2026 should expect:

• A meaningful search to find a willing prescribing physician or NP.
• Documentation of prior conventional treatment failures.
• A 2–8 week (or longer) SAP review timeline.
• Out-of-pocket costs of CAD $2,500–$6,500 for the program itself (Quebec RAMQ pathway is the exception).

ATMA CENA's intake call works through this realistically and does not promise outcomes the regulatory pathway does not support.

Frequently asked questions

Is psilocybin therapy legal in Canada? Yes — when accessed through the Health Canada Special Access Program (SAP). Psilocybin is Schedule III under the CDSA with no Health Canada approved indication; SAP is the only legal clinical pathway since the January 5, 2022 amendment. Recreational possession remains illegal.

Where can I get psilocybin therapy in Canada? SAP-pathway psilocybin therapy is delivered by clinicians with SAP authorization for individual patients. TheraPsil maintains a directory of trained clinicians; Roots to Thrive in Nanaimo BC offers group-based programs; Quebec providers including Drs. Farzin and Stephan have public funding precedent. ATMA CENA supports preparation and integration for patients pursuing the SAP pathway.

How does the SAP pathway work? A physician or nurse practitioner identifies an individual patient with a serious or life-threatening condition where conventional treatments have failed, completes the SAP request form, submits to Health Canada, and waits for case-specific authorization. The patient cannot apply directly. Once authorized, the practitioner sources the drug from a Canadian licensed supplier and administers it in a supervised clinical setting.

How much does psilocybin therapy cost? Roughly CAD $2,500–$6,500 per full program, including preparation, dosing, and integration. Filament Health provides synthetic psilocybin to SAP-approved Canadian patients at no charge — meaningfully reducing patient out-of-pocket relative to international markets.

Does insurance cover psilocybin therapy? Generally no. Quebec RAMQ has a public-funding precedent (Farzin / Stephan December 2022). VAC does NOT currently cover psilocybin-assisted therapy. Private insurance generally does not cover the drug; therapy fees may be partially covered as standard psychotherapy.

What conditions has Health Canada SAP approved psilocybin for? Most commonly: end-of-life distress, treatment-resistant depression. Less common: alcohol use disorder, OCD, anorexia, demoralization, cluster headache. PTSD-specific SAP applications more commonly target MDMA than psilocybin.

Does ATMA CENA directly administer psilocybin? The medical SAP application is initiated by the patient's prescribing physician or nurse practitioner, and the dosing session is delivered under that practitioner's authorization. ATMA CENA's role is supporting preparation and integration, training clinicians, and (where appropriate) coordinating care arrangements with patients' existing prescribers and therapists.

How is psilocybin therapy different from ketamine therapy? Psilocybin is a 5-HT2A serotonin agonist with longer (6–8 hour) sessions, classic psychedelic experience, fewer dosing sessions per program, and SAP-only access. Ketamine is an NMDA antagonist with shorter (90–120 minute) sessions, dissociative experience, more dosing sessions per acute course (4–8), and broader access (off-label for generic; Spravato Health Canada-approved for TRD). See Ketamine vs Psilocybin Therapy.

What if I'm in palliative care — is psilocybin therapy something I can pursue? End-of-life distress is the foundation indication for Canadian psilocybin SAP approvals. The published evidence base (Griffiths 2016, Ross 2016, Agin-Liebes 2020 long-term follow-up, Agrawal 2024 group therapy) is the strongest in this domain. The pathway requires a prescribing physician (often palliative or psychiatric) willing to apply for SAP. See Psilocybin Therapy for End-of-Life Distress for detail.

What about microdosing? Microdosing — taking sub-perceptual psilocybin doses on a recurring schedule — has popular interest but does not have published clinical evidence comparable to high-dose therapeutic protocols. Microdosing is not part of the SAP-pathway clinical model. See the upcoming Wave 3 microdosing article for honest framing.

Can I use psilocybin mushrooms instead? Recreational psilocybin mushrooms are illegal under CDSA Schedule III. Clinical protocols use synthetic pharmaceutical psilocybin from licensed Canadian producers (Filament, Optimi, Psyence) for safety, dose precision, and regulatory compliance. The clinical-vs-recreational distinction matters legally, pharmacologically, and operationally.

What are the risks? Acute psychiatric distress during dosing ("challenging experiences"), transient blood pressure elevation, mild nausea, fatigue post-session. Serious adverse events in published trials are rare. Pre-treatment screening rules out absolute contraindications (psychotic disorder history, cardiovascular disease, pregnancy, concurrent lithium). See the upcoming Wave 3 side-effects article for the safety profile.

Sources

1. ATMA CENA — Psychedelic-Assisted Therapy: https://psychedelic.healthcare/
2. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
3. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
4. Government of Canada — Psilocybin and psilocin: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html
5. TheraPsil: https://therapsil.ca/
6. PsyCan / Psychedelics Canada: https://psychedelicscanada.org/
7. Filament Health: https://filament.health/
8. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
9. Ross S, et al. (2016). Psilocybin in cancer-related anxiety/depression. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909165/
10. Agin-Liebes GI, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy in cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/31916890/
11. Agrawal M, et al. (2024). Psilocybin-assisted group therapy for cancer-related MDD. Cancer. https://pubmed.ncbi.nlm.nih.gov/38105655/
12. Anderson BT, et al. (2020). Psilocybin-assisted group therapy for demoralization in AIDS survivors. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/33150319/
13. Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state — DMN. PNAS. https://pubmed.ncbi.nlm.nih.gov/22308440/
14. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Mystical experience predicts psilocybin therapeutic efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
15. MacLean KA, Johnson MW, Griffiths RR (2011). Mystical Experience Questionnaire validation. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/21674151/
16. Goodwin GM, et al. (2022). COMP360 psilocybin in TRD (Phase 2b RCT). NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
17. Bogenschutz MP, et al. (2022). Psilocybin-assisted therapy for alcohol use disorder. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625

Related articles in this cluster

• What Is Psilocybin Therapy?
• How to Access Psilocybin Therapy in Canada (SAP)
• Psilocybin-Assisted Therapy Cost in Canada
• Psilocybin Therapy for End-of-Life Distress
• Ketamine vs Psilocybin Therapy
• Find care near you
• Psychedelic Therapy Training in Canada

Last updated: 2026-05-06